TL;DR
This study provides a comprehensive, up-to-date analysis of colorectal cancer (CRC) burden globally from 1990-2021, using the GBD 2021 dataset. It highlights significant regional disparities and identifies key risk factors, particularly dietary and behavioral ones, while also projecting a substantial decline in CRC burden by 2051.
What Problem Does This Paper Address?
Colorectal cancer (CRC) is a major global health challenge, ranking as the third most diagnosed cancer and the second leading cause of cancer-related mortality. While previous studies have shed light on its epidemiology, they often suffer from limitations such as outdated data, insufficient regional granularity, and the use of deterministic projection models that fail to fully capture complex temporal trends. These limitations hinder effective public health interventions and resource allocation. This paper aims to address these gaps by providing a more detailed, up-to-date, and methodologically advanced analysis of CRC burden and its risk factors across global, regional, and national levels.
Methods
The researchers employed a systematic analysis using data from the Global Burden of Disease (GBD) 2021 study, covering 204 countries and territories from 1990 to 2021. A key methodological advancement was the use of a Bayesian age-period-cohort (BAPC) model, enhanced with several innovations:
- Time-varying risk elasticities: This allows for dynamic linking of temporal trends in modifiable risk factors (like smoking and processed meat intake) to disease burden.
- Penalized complexity (PC) priors: These stabilize estimates, particularly in regions with sparse data, reducing the risk of overfitting.
- Integrated Nested Laplace Approximation (INLA): This computationally efficient method is used for Bayesian inference on large datasets.
The BAPC model was used to project CRC trends over the next three decades. Statistical analyses involved calculating age-standardized incidence rates (ASIR), age-standardized mortality rates (ASMR), and age-standardized disability-adjusted life years rates (ASDR), with uncertainty intervals generated via Monte Carlo simulations.
Datasets
The primary dataset used in this study is the Global Burden of Disease (GBD) 2021 dataset. This comprehensive dataset includes:
- Incidence rates, mortality rates, and disability-adjusted life years (DALYs) for 371 diseases and injuries, including CRC.
- Data spanning 204 countries and territories from 1990 to 2021.
- Information integrated from 3,621 sources, including population-based cancer registries, vital registration systems, hospital records, and national health surveys.
The GBD 2021 dataset is noted for its updated temporal coverage (up to 2021), capturing the impact of the COVID-19 pandemic, and its adjustments for known biases and disruptions.
Key Insights and Ideas
- Significant Regional Disparities: The burden of CRC is not uniform globally, with notable differences in incidence, mortality, and DALYs across GBD regions. Central Europe, for instance, shows a particularly high burden.
- Dominance of Behavioral and Dietary Risks: Behavioral risks (like smoking and high alcohol use) and dietary risks (especially low whole grain intake and high processed meat consumption) are identified as the most impactful factors contributing to CRC burden.
- Projected Decline in CRC Burden: The study forecasts a substantial decrease in global CRC incidence, mortality, and DALY rates by 2051, offering a hopeful outlook for current health initiatives.
- Gender Disparities Persist: Males consistently show a higher burden of CRC compared to females, a discrepancy attributed to a combination of biological factors, lifestyle choices, and potentially hormonal influences.
- Importance of Socio-Demographic Index (SDI): The study highlights how SDI influences CRC burden, with low and medium SDI regions experiencing an increase in burden despite overall global declines in ASMR and ASDR.
- Methodological Advancement: The use of a Bayesian age-period-cohort model with enhanced features allows for a more nuanced understanding of CRC trends and more reliable future projections compared to previous deterministic models.
Key Results
- Global Burden in 2021: Approximately 2,194,143 CRC cases, with a prevalence of 11,679,120 and 24,401,100 DALYs.
- Upward Trends (1990-2021): Age-standardized incidence, mortality, and DALY rates for CRC showed upward trends, particularly in males.
- Regional Hotspots: Central Europe exhibited the highest burden, with incidence peaking in individuals aged 84-94 years.
- Risk Factor Contributions: Central Europe showed the highest contribution from risk factors (305.66 per 100,000 population). Behavioral risks were the most significant, followed by dietary and metabolic risks.
- Projected Burden by 2051: Global ASIR, ASMR, and ASDR are projected to be 18.21, 7.10, and 165.21 per 100,000 population, respectively, with the burden remaining higher in males.
Limitations and Future Work
- Data Uncertainty: The authors acknowledge that estimates for regions with historically limited cancer registration (e.g., Sub-Saharan Africa) have wider uncertainty intervals, reflecting the inherent data limitations.
- Hereditary Factors and Molecular Subtypes: The GBD data does not include information on hereditary CRC syndromes or molecular subtypes, limiting the assessment of genetic contributions to CRC burden. Future research should integrate genomic epidemiology for more comprehensive burden estimates.
- Policy Modeling: Explicit counterfactual policy modeling was beyond the scope of this study, though the findings provide evidence to support prioritization of prevention strategies.
- Projection Assumptions: Future projections assume no disruptive technological breakthroughs (e.g., liquid biopsy adoption), meaning results are conservative estimates requiring periodic recalibration.
- Future Research Directions:
- Refining projections and exploring underlying reasons for regional disparities.
- Integrating multi-omics data with population-level analyses to clarify mechanisms behind CRC disparities, especially in early-onset cases.
- Developing robust systems for monitoring early-onset CRC trends.
- Conducting dedicated analyses on the interdependence of risk factors.
Summary updated